Treating TB in India: plan to reward private doctors
With tuberculosis (TB) emerging as India’s biggest health threat, the Union health ministry plans to pay every private doctor who successfully treats a TB patient.
Prepared by the central TB division of the health ministry, the new TB control strategy aims to drastically bring down the number of TB cases and deaths by 2025.
India has an estimated 28 lakh TB patients, of which almost 10
lakh patients are “missing” from government
records.
This means that the national TB control
programme does not know if these 10 lakh patients are getting
any treatment at all, and if they are, what the quality of the
treatment is.
To track these missing cases, the
strategy puts top priority on increased engagement with the
private doctors — the first port of call for the majority
of Indian patients. At least 50% TB patients in India are
treated first by the private doctors.
For
successfully treating a drug-responsive TB patient, the proposal
asks to give a cash reward of up to Rs 2,750 to the private
doctor. For treating a drug-resistant patient, the incentive can
be up to Rs 6,750.
This includes Rs 250 for notifying
the case to the government and Rs 250 every month till the
successful completion of the treatment. A drug-responsive TB
case may take seven to 10 months for treatment whereas the
treatment of a drug-resistant TB patient can take up to two
years.
In 2012, the government made it mandatory for
private doctors to report the TB cases they treat to the
government. Even though the initial response was lukewarm, the
number of reportings rose in the last couple of years; even so,
lakhs of cases are missing from the system.
“We
know very little about private sector TB care. There is only one
available study on TB treatment outcomes in the private sector,
which showed that only about 50% of TB patients in the private
sector complete the 6-month course prescribed in TB therapy.
This is much lower than the 70%-80% treatment completion rate in
the government sector,” Ramanath Subbaraman, a TB
researcher from the Harvard Medical School in the US told DH.
Source:
Deccan Herald